Cargando…
Successful treatment of advanced ovarian cancer with anlotinib: a case report
Ovarian cancer remains the most lethal gynecological malignant tumor, with relapse occurring in approximately 70% of advanced cases. Anlotinib is an oral small-molecule multi-targeted tyrosine kinase inhibitor that can resist neoangiogenesis and inhibit tumor growth. Previous research demonstrated c...
Autores principales: | Zhang, Ping, Ma, Liangliang, Wang, Xiaojie, Zhang, Ruijie, Dong, Yuting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724413/ https://www.ncbi.nlm.nih.gov/pubmed/33284728 http://dx.doi.org/10.1177/0300060520976824 |
Ejemplares similares
-
Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023) -
Anlotinib is effective in the treatment of advanced carcinoma ex pleomorphic adenoma of the submandibular gland
por: Song, Shujie, et al.
Publicado: (2019) -
Case report of severe pneumothorax due to lung cancer treated with anlotinib
por: Lu, Haowei, et al.
Publicado: (2023) -
Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022) -
A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma
por: Zou, Jieya, et al.
Publicado: (2021)